• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Future of sepsis therapies.脓毒症治疗的未来。
Crit Care. 2016 Apr 22;20(1):106. doi: 10.1186/s13054-016-1274-9.
2
Mediator-specific therapies for the systemic inflammatory response syndrome, sepsis, severe sepsis, and septic shock: present and future approaches.针对全身炎症反应综合征、脓毒症、严重脓毒症和感染性休克的介质特异性疗法：现状与未来方法。
Crit Care Nurs Clin North Am. 1994 Jun;6(2):309-19.
3
Clinical trials of immunomodulatory therapies in severe sepsis and septic shock.严重脓毒症和脓毒性休克免疫调节治疗的临床试验
Clin Infect Dis. 2002 Apr 15;34(8):1084-93. doi: 10.1086/339549. Epub 2002 Mar 12.
4
The International Sepsis Forum's controversies in sepsis: how will sepsis be treated in 2051?国际脓毒症论坛关于脓毒症的争议：2051年脓毒症将如何治疗？
Crit Care. 2002 Aug;6(4):277-8. doi: 10.1186/cc1506. Epub 2002 Jun 10.
5
Immunotherapy of sepsis.脓毒症的免疫治疗
Lancet Infect Dis. 2001 Oct;1(3):165-74. doi: 10.1016/S1473-3099(01)00093-7.
6
Early fluid resuscitation in sepsis: evidence and perspectives.脓毒症的早期液体复苏：证据与观点。
Shock. 2010 Sep;34 Suppl 1:40-3. doi: 10.1097/SHK.0b013e3181e7e668.
7
Early biomarker activity in severe sepsis and septic shock and a contemporary review of immunotherapy trials: not a time to give up, but to give it earlier.严重脓毒症和感染性休克的早期生物标志物活性及免疫治疗试验的当代综述：现在不是放弃的时候，而是更早开始治疗的时候。
Shock. 2013 Feb;39(2):127-37. doi: 10.1097/SHK.0b013e31827dafa7.
8
Extracorporeal renal replacement therapies in the treatment of sepsis: where are we?体外肾脏替代疗法在脓毒症治疗中的应用现状：我们进展到哪一步了？
Semin Nephrol. 2015 Jan;35(1):55-63. doi: 10.1016/j.semnephrol.2015.01.006.
9
New strategies for combatting sepsis: the magic bullets missed the mark ... but the search continues.对抗败血症的新策略：神奇子弹未命中目标……但搜索仍在继续。
Trends Biotechnol. 1995 Feb;13(2):56-63. doi: 10.1016/S0167-7799(00)88906-4.
10
Biomarkers of sepsis.脓毒症的生物标志物
Crit Care Med. 2009 Jul;37(7):2290-8. doi: 10.1097/CCM.0b013e3181a02afc.

引用本文的文献

1
Anti-Inflammatory Effects of Anthocyanin-Enriched Black Soybean Seed Coat (BSSC) Crude Extract on LPS-Induced Acute Liver Injury in Mice.富含花青素的黑豆种皮（BSSC）粗提物对脂多糖诱导的小鼠急性肝损伤的抗炎作用
Antioxidants (Basel). 2024 Mar 1;13(3):311. doi: 10.3390/antiox13030311.
2
Co-expression module analysis reveals high expression homogeneity for both coding and non-coding genes in sepsis.共表达模块分析揭示了脓毒症中编码基因和非编码基因的高表达同质性。
BMC Genomics. 2023 Jul 24;24(1):418. doi: 10.1186/s12864-023-09460-9.
3
Homeodomain-interacting protein kinase 2 regulates NLRP3 inflammasome activation through endoplasmic reticulum stress in septic liver injury.同源结构域相互作用蛋白激酶 2 通过内质网应激调控脓毒症肝损伤中 NLRP3 炎性体激活。
J Int Med Res. 2023 May;51(5):3000605231173272. doi: 10.1177/03000605231173272.
4
ANXA1sp Protects against Sepsis-Induced Myocardial Injury by Inhibiting Ferroptosis-Induced Cardiomyocyte Death via SIRT3-Mediated p53 Deacetylation.ANXA1sp 通过 SIRT3 介导的 p53 去乙酰化抑制铁死亡诱导的心肌细胞死亡来保护脓毒症诱导的心肌损伤。
Mediators Inflamm. 2023 Apr 4;2023:6638929. doi: 10.1155/2023/6638929. eCollection 2023.
5
Embracing complexity in sepsis.脓毒症中的复杂性。
Crit Care. 2023 Mar 11;27(1):102. doi: 10.1186/s13054-023-04374-0.
6
Mortality and Sequential Organ Failure Assessment Score in Patients With Suspected Sepsis: The Impact of Acute and Preexisting Organ Failures and Infection Likelihood.疑似脓毒症患者的死亡率及序贯器官衰竭评估评分：急性和既往存在的器官衰竭及感染可能性的影响
Crit Care Explor. 2023 Feb 21;5(2):e0865. doi: 10.1097/CCE.0000000000000865. eCollection 2023 Feb.
7
Lung-Brain Crosstalk in Sepsis: Protective Effect of Prophylactic Physical Exercise Against Inflammation and Oxidative Stress in Rats.脓毒症中的肺脑交互作用：预防性体力活动对大鼠炎症和氧化应激的保护作用。
Mol Neurobiol. 2022 Jun;59(6):3860-3872. doi: 10.1007/s12035-022-02823-5. Epub 2022 Apr 15.
8
Whole blood transcriptomic investigation identifies long non-coding RNAs as regulators in sepsis.全血转录组学研究确定长链非编码RNA为脓毒症的调节因子。
J Transl Med. 2020 May 29;18(1):217. doi: 10.1186/s12967-020-02372-2.
9
Overexpression of homeodomain-interacting protein kinase 2 (HIPK2) attenuates sepsis-mediated liver injury by restoring autophagy.同源结构域相互作用蛋白激酶 2（HIPK2）过表达通过恢复自噬来减轻脓毒症介导的肝损伤。
Cell Death Dis. 2018 Aug 28;9(9):847. doi: 10.1038/s41419-018-0838-9.
10
Sophocarpine Attenuates LPS-Induced Liver Injury and Improves Survival of Mice through Suppressing Oxidative Stress, Inflammation, and Apoptosis.苦参碱通过抑制氧化应激、炎症和细胞凋亡减轻 LPS 诱导的肝损伤并提高小鼠的存活率。
Mediators Inflamm. 2018 May 16;2018:5871431. doi: 10.1155/2018/5871431. eCollection 2018.

本文引用的文献

1
Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study.败血症患者个体宿主反应和结局的基因组图谱：一项前瞻性队列研究。
Lancet Respir Med. 2016 Apr;4(4):259-71. doi: 10.1016/S2213-2600(16)00046-1. Epub 2016 Feb 23.
2
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).《脓毒症及脓毒性休克第三次国际共识定义（脓毒症-3）》
JAMA. 2016 Feb 23;315(8):801-10. doi: 10.1001/jama.2016.0287.
3
Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial.白细胞介素-1受体阻断与具有巨噬细胞活化综合征特征的脓毒症患者死亡率降低相关：对一项既往III期试验的重新分析
Crit Care Med. 2016 Feb;44(2):275-81. doi: 10.1097/CCM.0000000000001402.
4
Sepsis: a roadmap for future research.脓毒症：未来研究的路线图。
Lancet Infect Dis. 2015 May;15(5):581-614. doi: 10.1016/S1473-3099(15)70112-X. Epub 2015 Apr 19.
5
Sepsis: current dogma and new perspectives.脓毒症：现有定论与新视角。
Immunity. 2014 Apr 17;40(4):463-75. doi: 10.1016/j.immuni.2014.04.001.
6
Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012.2000-2012 年澳大利亚和新西兰重症监护病房严重脓毒症和脓毒性休克患者的死亡率。
JAMA. 2014 Apr 2;311(13):1308-16. doi: 10.1001/jama.2014.2637.
7
Interplay between sepsis and chronic health.脓毒症与慢性健康之间的相互作用。
Trends Mol Med. 2014 Apr;20(4):234-8. doi: 10.1016/j.molmed.2014.02.005. Epub 2014 Mar 14.
8
Why have clinical trials in sepsis failed?为什么脓毒症临床试验会失败？
Trends Mol Med. 2014 Apr;20(4):195-203. doi: 10.1016/j.molmed.2014.01.007. Epub 2014 Feb 24.
9
Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy.脓毒症导致的免疫抑制：从细胞功能障碍到免疫治疗。
Nat Rev Immunol. 2013 Dec;13(12):862-74. doi: 10.1038/nri3552. Epub 2013 Nov 15.
10
Benchmarking the incidence and mortality of severe sepsis in the United States.美国严重脓毒症发病率和死亡率的基准研究。
Crit Care Med. 2013 May;41(5):1167-74. doi: 10.1097/CCM.0b013e31827c09f8.

Future of sepsis therapies.

作者信息

van der Poll Tom

机构信息

Academic Medical Center, University of Amsterdam, Division of Infectious Diseases & Center of Experimental and Molecular Medicine, Meibergdreef 9, Room G2-129, 1105 AZ, Amsterdam, The Netherlands.

出版信息

Crit Care. 2016 Apr 22;20(1):106. doi: 10.1186/s13054-016-1274-9.

DOI:10.1186/s13054-016-1274-9
PMID:27103307
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4841050/
Abstract
摘要